Search
Hydroxyethyl ethylcellulose
go.drugbank.com/drugs/DB14139ApprovedHydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.
Betulinic Acid
go.drugbank.com/drugs/DB12480ApprovedWithdrawnBetulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.
NE-180
go.drugbank.com/drugs/DB05619ExperimentalNE-180 was under investigation in a clinical trial conducted in the European Union.
KB001
go.drugbank.com/drugs/DB05222InvestigationalKB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated
Ciglitazone
go.drugbank.com/drugs/DB09201ExperimentalDeveloped by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. … Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market.
Mirococept
go.drugbank.com/drugs/DB06492ExperimentalIt is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation … It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the
Maxy-G34
go.drugbank.com/drugs/DB05718Investigational, while Neulasta has a single 20 Kd PEG group attached at the N terminal end of the wild type G-CSF protein. … wild type human G-CSF to avoid PEGylation of such sites.
Palifosfamide
go.drugbank.com/drugs/DB05668InvestigationalIfosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
S-8510
go.drugbank.com/drugs/DB06504ExperimentalS-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide
go.drugbank.com/drugs/DB06945ExperimentalThis compound belongs to the diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. … This substance is known to target a disintegrin and metalloproteinase with thrombospondin motifs 5.